A Study of Ragweed (Ambrosia Artemisiifolia) Allergy Immunotherapy Tablet in Adults With Ragweed Allergies (P05751)
Status:
Completed
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
This study assessed the safety profile of short ragweed (Ambrosia artemisiifolia) in
participants with ragweed-induced rhinoconjunctivitis with or without asthma. The primary
objective was to compare treatment-emergent adverse events (AEs) for participants treated
with short ragweed allergy immunotherapy tablet (AIT) with those treated with placebo.